Prof. Wenbin Lin on the List of “Researchers to Know” Selected by the Illinois Science & Technology Coalition

/ October 14, 2018/ News and Events

Illinois Science & Technology Coalition (ISTC) has selected university researchers whose research efforts have had significant impacts in their fields, from advancing new treatments in medicine and tackling cancer to revolutionizing computing and shaping new technologies in the 21st century. Prof. Wenbin Lin, Founder and Chairman of RiMO Therapeutics, was featured in ISTC’s first annual list of “Researchers to Know” for his pioneering work in designing functional materials based on metal-organic frameworks (MOFs), particularly for discovering MOF materials to enhance X-ray radiotherapy on the bench side and bringing them to the bed side to treat cancer patients. For more information: https://www.istcoalition.org/data/2018-researchers-to-know/

First Patient Enrolled in Phase 1 Study of RiMO-301

/ July 13, 2018/ News and Events, RiMO-301

Elk Grove Village, Il.–July 13, 2018– RiMO Therapeutics Inc., a privately held oncology drug development company and a pioneer in Radio-immuno Metal-Organic (RiMO) technology-based cancer immunotherapy, today announced that the first patient has been dosed in a Phase 1 study of RiMO-301 in patients with advanced tumors. RiMO-301 enhances the efficacy of X-ray radiotherapy via the unprecedented radiotherapy-radiodynamic therapy (RT-RDT) mode of action. “Initiation of this study represents not only a significant milestone for RiMO Therapeutics but also the field of nanoscale metal-organic frameworks (nMOFs), as RiMO-301 is the first nMOF-based product to enter clinical trials.” said Wenbin Lin, Ph.D., founder and chairman of RiMO and also the James Franck Professor of Chemistry, Radiation & Cellular Oncology, and the Ludwig Center for Metastasis Research at

Read More

Chemical and Engineering News Feature

/ March 29, 2018/ News and Events

Chemical and Engineering News featured the proprietary RiMO technology for its ability to generate two types of tumor-fighting reactive oxygen species with deeply penetrating X-rays and to activate T cells to attack tumor tissue systemically.

UChicago News Feature

/ March 29, 2018/ News and Events

Proprietary RiMO technology was featured in UChicago News for its ability to significantly reduce X-ray doses used in radiotherapy and enhance checkpoint blockade immunotherapy.